Themes Robotics & Automation ETF (NASDAQ: BOTT)

Latest news for Themes Robotics & Automation ETF (NASDAQ:BOTT)

The Fund employs a passive management (or indexing) investment approach designed to track the performance, before fees and expenses, of the Solactive Industrial Robotics & Automation Index, or any successor thereto (the Index). The Index is based on a proprietary methodology developed and maintained by Solactive AG (the Index Provider), which is an organization that is independent of, and unaffiliated with, the Fund and Themes Management Company, LLC, the Funds investment adviser (the Adviser).

Credo Technology Group Holding Ltd

Nvidia Corp.

Halma Plc

Qualcomm Inc.

Comet Holding Ag

Macom Technology Solutions Holdings, Inc.

Renesas Electronics Corp

Konecranes Oyj

Silicon Motion Technology Corp., ADR

Themes Robotics & Automation ETF

Endpoint,Security,-,Endpoint,Protection,Concept,-,Multiple,Devices,Secured

Earnings

Equities

Large Cap

News

Guidance

Movers

BOTT

CZAR

Fortive Corporation (NYSE: FTV) reported Q4 results with revenue of $1.62B, missing consensus. EPS of $1.17 beat expectations. Company expects revenue of $6.23B-$6.35B for FY25.

Fortive Q4: EPS Tops, Revenue Misses, CEO Confident In 2025 Recovery

Botto

Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) has outperformed the market over the past 10 years by 1.55% on an annualized basis producing an average annual return of 12.69%. Currently, Commercial Metals has a market capitalization of $5.64 billion. 
Buying $1000 In CMC: If an investor had bought $1000 of CMC stock 10 years ago, it would be worth $3,418.04 today based on a price of $49.63 for CMC at the time of writing.
<h3>Commercial Metals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738971010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Commercial Metals 10 Years Ago Would Be Worth This Much Today

Barrington Research analyst Gary Prestopino maintains DHI Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHX#NYSE">DHX</a>) with a Outperform and maintains $7 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on DHI Group, Maintains $7 Price Target

Macquarie analyst Chad Beynon maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Neutral and raises the price target from $248 to $260.

Macquarie Maintains Neutral on Hilton Worldwide Holdings, Raises Price Target to $260

TD Securities analyst Vince Valentini maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Hold and raises the price target from C$31 to C$33.

TSX:BCE

TD Securities Maintains Hold on BCE, Raises Price Target to C$33

TD Securities analyst Vince Valentini maintains Thomson Reuters (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TRI#TSX">TRI</a>) with a Hold and raises the price target from C$250 to C$260.

TSX:TRI

TD Securities Maintains Hold on Thomson Reuters, Raises Price Target to C$260

Citigroup analyst Ronald Josey maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and lowers the price target from $275 to $273.

AMZN

Citigroup Maintains Buy on Amazon.com, Lowers Price Target to $273

Citigroup analyst David Lebowitz initiates coverage on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Neutral rating and announces Price Target of $38.

Initiation

VKTX

Citigroup Initiates Coverage On Viking Therapeutics with Neutral Rating, Announces Price Target of $38

Citigroup analyst David Lebowitz initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy rating and announces Price Target of $86.

CYTK

Citigroup Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $86

Citigroup analyst Andrew Kaplowitz initiates coverage on Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Buy rating and announces Price Target of $795.

Citigroup Initiates Coverage On Parker Hannifin with Buy Rating, Announces Price Target of $795

Maxim Group analyst Naz Rahman maintains Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and lowers the price target from $120 to $70.

Maxim Group Maintains Buy on Viking Therapeutics, Lowers Price Target to $70

Maxim Group analyst Tom Forte maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $260 to $280.

Maxim Group Maintains Buy on Amazon.com, Raises Price Target to $280

Lake Street analyst Jaeson Schmidt maintains Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) with a Buy and lowers the price target from $6 to $5.

LTRX

Lake Street Maintains Buy on Lantronix, Lowers Price Target to $5

Lake Street analyst Eric Martinuzzi maintains QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) with a Hold and raises the price target from $25 to $27.

QNST

Lake Street Maintains Hold on QuinStreet, Raises Price Target to $27

Lake Street analyst Ben Klieve maintains Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) with a Buy and lowers the price target from $13 to $8.

BIOX

Lake Street Maintains Buy on Bioceres Crop Solutions, Lowers Price Target to $8

Loop Capital analyst Garik Shmois maintains Advanced Drainage Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) with a Buy and lowers the price target from $170 to $160.

Loop Capital Maintains Buy on Advanced Drainage Systems, Lowers Price Target to $160

Loop Capital analyst Gary Mobley maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Buy and raises the price target from $660 to $760.

MPWR

Loop Capital Maintains Buy on Monolithic Power Systems, Raises Price Target to $760

Loop Capital analyst Yun Kim maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Hold and lowers the price target from $150 to $140.

QLYS

Loop Capital Maintains Hold on Qualys, Lowers Price Target to $140

Barclays analyst Jeffrey Bernstein maintains Yum Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) with a Overweight and raises the price target from $162 to $165.

Barclays Maintains Overweight on Yum Brands, Raises Price Target to $165

Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) has outperformed the market over the past 5 years by 8.66% on an annualized basis producing an average annual return of 21.03%. Currently, Ovintiv has a market capitalization of $11.07 billion. 
Buying $100 In OVV: If an investor had bought $100 of OVV stock 5 years ago, it would be worth $259.90 today based on a price of $42.52 for OVV at the time of writing.
<h3>Ovintiv's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738968308_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Ovintiv 5 Years Ago Would Be Worth This Much Today

Barclays analyst Benjamin Budish maintains Tradeweb Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) with a Overweight and lowers the price target from $154 to $149.

Barclays Maintains Overweight on Tradeweb Markets, Lowers Price Target to $149

Fortive Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) shares are trading lower after the company&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43557376/fortive-reports-strong-fourth-quarter-and-full-year-2024-results-introduces-first-quarter-and-full" rel="noreferrer noopener">reported&nbsp;fourth-quarter&nbsp;results</a>.



Revenue grew&nbsp;2% year-over-year (Y/Y) to $1.620 billion,&nbsp;missing the consensus of&nbsp;$1.624 billion.



Core Growth Sales by segments: Intelligent Operating Solutions $710.8 million (+<a href="https://d1io3yog0oux5.cloudfront.net/_b6473ba34b04e3c63d57920de052a56b/fortive/db/924/11185/pdf/FTV-4Q-2024-Earnings-Presentation.pdf" target="_blank" rel="noreferrer noopener">4.1</a>% Y/Y), Precision Technologies $567.7 million (-0.4% Y/Y) and Advanced Healthcare Solutions $341.8 million (+3.2% Y/Y).



The company&#8217;s adjusted operating margin is up 100 basis points Y/Y to 28.7% in the quarter. Adjusted EPS of $1.17, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">beating the consensus of $1.12</a>. It also reported an operating cash flow of $502 million and a free cash flow of $465 million in the quarter.



&#8220;Continued growth in our Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) segments was driven by steady demand for our safety and productivity solutions and increased contributions from FBS-driven product innovations,&#8221; said James A. Lico, president and CEO.



&#8221;We saw strong order growth across all of our segments, including the second consecutive quarter of double-digit orders growth for our Precision Technologies (PT) segment. This momentum drove sequential improvement in PT core growth and supports our view of a gradual recovery as we move through 2025.&#8221;



Outlook:&nbsp;For FY25, Fortive expects revenue of $6.23&nbsp;billion&nbsp;–&nbsp;$6.35&nbsp;billion&nbsp;versus a consensus of&nbsp;$6.488 billion and adjusted EPS&nbsp;of&nbsp;$4.00&nbsp;–&nbsp;$4.12&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">versus the consensus of&nbsp;$3.85</a>.



For the&nbsp;first quarter&nbsp;of FY25, Fortive anticipates revenue of&nbsp;$1.48 billion –$1.51 billion&nbsp;(consensus:&nbsp;$1.565 billion) and adjusted EPS of&nbsp;$0.83 –&nbsp;$0.86 (consensus&nbsp;$0.91).



Investors can gain exposure to the stock via&nbsp;Themes Natural Monopoly ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZAR#NASDAQ">CZAR</a>) and Themes Robotics &amp; Automation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTT#NASDAQ">BOTT</a>).



Price Action:&nbsp;FTV shares are down 3.57% at $76.99 premarket at the last check Friday.



Read Next:



<ul>
<li><a href="https://www.benzinga.com/25/01/43335937/palo-alto-taiwan-semiconductor-fortive-and-a-major-financial-stock-on-cnbcs-final-trades" target="_blank" rel="noreferrer noopener">Palo Alto, Taiwan Semiconductor, Fortive And A Major Financial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>



Photo: Shutterstock

Comments

Themes Robotics & Automation ETF

News

Latest news for Themes Robotics & Automation ETF (NASDAQ:BOTT)

Friday, February 07, 2025

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga